Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.

Complete 36-week results from the ASPIRE study involving 52 patients are expected in the second quarter of 2025.

Shares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Intravitreal UBX1325 helped patients with diabetic macular edema gain vision but failed to meet its primary analysis endpoint in the ASPIRE clinical trial, according to a press release from Unity ...

The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with diabetic macular edema (DME) who had poor ...

UNITY Biotechnology (UBX) announced topline results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient populationUBX1325 was ...

UNITY Biotechnology, Inc. has announced a virtual investor event scheduled for March 24, 2025, at 8:00 AM ET, featuring Dr. Robert Bhisitkul from UCSF School of Medicine and company management.

SOUTH SAN FRANCISCO - UNITY Biotechnology, Inc. [NASDAQ: UBX], a small-cap biotechnology company with a market capitalization of approximately $31 million, announced today that its Phase 2b ASPIRE ...

SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse ...